Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody combo takes on advanced solid tumors

NCT ID NCT06819735

Disease control Sponsor: Domain Therapeutics Australia Pty Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called DT-7012, alone or with another cancer drug (an immune checkpoint inhibitor), in 125 adults with advanced solid tumors that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors. It is an early-stage trial, so results will guide further research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DT-7012 (an anti-CCR8 antibody) and an immune checkpoint inhibitor
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects, including immune-related reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor, among selected cancer types, that is recurrent, locally advanced (i.e., not eligible for curative surgery or radiotherapy) or metastatic, has progressed after at least one line of systemic therapy and has no established curative option. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the local site investigator/radiologist. * At least 1 tumour lesion accessible to biopsy per treating physician judgement. * Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1. * Adequate organ function. Exclusion Criteria: * Any unresolved AEs from previous anti-cancer therapies of grade ≥2, with the exception of alopecia. * Prior severe immune-related AEs (irAEs) leading to immunotherapy treatment discontinuation. * Major surgery or significant traumatic injury within 4 weeks prior to Cycle 1 Day 1 with unadequately recovered AEs and/or complications from the intervention prior to Cycle 1 Day 1. * Prior radiotherapy within the 4 weeks prior to Cycle 1 Day 1 or limited field palliative radiotherapy within 2 weeks prior to Cycle 1 Day 1. * Prior anti-CCR8 monoclonal antibody treatment received in an investigational trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced solid tumors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cabrini Health Limited

    RECRUITING

    Malvern, Victoria, 3144, Australia

  • Cancer Research SA

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Honor Health Research Institute

    NOT_YET_RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Hôpitaux Universitaires de Strasbourg

    RECRUITING

    Strasbourg, 67200, France

  • Institut Bergonié

    RECRUITING

    Bordeaux, 33076, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, 94800, France

  • Macquarie University Clinical Trial Unit

    RECRUITING

    North Ryde, New South Wales, 2109, Australia

  • One Clinical Research Pty Ltd

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Peninsula & South Eastern Haematology & Oncology Group

    RECRUITING

    Frankston, Victoria, 3199, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.